leadf
logo-loader
viewCanaccord Genuity

MindMed announces $25M bought-deal offering to finance development of its psychedelic-assisted therapies and medicines

New York-based MindMed has entered into an agreement with lead underwriter Canaccord Genuity to purchase 23,810,000 units at C$1.05 apiece

Canaccord Genuity - MMindMed) Inc announces $25 million bought-deal offering to finance development of its psychedelic-assisted therapies and medicines
The offering allows for an over-allotment for additional proceeds of C$3,750,075

Mind Medicine (MindMed) Inc (NEO:MMED) (OTCMKTS:MMEDF) announced Friday a $25 million bought-deal offering to finance the development of its psychedelic-assisted therapies and medicines.

In a statement, New York-based MindMed said it has entered into an agreement with lead underwriter Canaccord Genuity Corp and a syndicate of underwriters to purchase 23,810,000 units at C$1.05 apiece. 

Each unit shall consist of one subordinate voting share and one-half of one subordinate share purchase warrant, exercisable to acquire one subordinate voting share at C$1.40 apiece for a period of 36 months from the closing of the offering.

READ: Mind Medicine to commit $5M to launch and develop clinical training program in psychedelic therapies and medicine

MindMed said it has granted the underwriters an option to purchase up to an additional 3,571,500 units at the issue price, exercisable at any time, for a period of 30 days after and including the closing date. Such a move would result in additional proceeds of C$3,750,075. The over-allotment option is exercisable to acquire units, subordinate voting shares, and/or warrants (or any combination thereof) at the discretion of the lead underwriter.

The underwriters are to be paid a cash commission equal to 6% of the gross proceeds and to receive unit purchase warrants equal to 6% of the number of units sold, with each underwriters' warrant being exercisable to acquire one unit at the issue price for 36 months from the closing slated for October 30.

Part of the proceeds from the offering will help fund ongoing research and development work on psilocybin in collaboration with the University Hospital Basel's Liechti Lab in Switzerland to better understand and compare the altered states of consciousness induced by psilocybin and LSD. Also, the money will go towards the development of 18-MC, a non-hallucinogenic molecule derivative of ibogaine from the African plant iboga, as a way to treat opioid use disorder. 

Contact the author: patrick@proactiveinvestors.com

Follow him on Twitter @PatrickMGraham

Quick facts: Canaccord Genuity

Price: 8.77 CAD

TSX:CF
Market: TSX
Market Cap: $849.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Sativa Wellness Group salute EU court ruling that CBD is not classified as...

Sativa Wellness Group Inc's (LON:SWEL) Henry Lees-Buckley talks to Proactive London about the latest ruling from the European Court of Justice (ECJ) that CBD is not classified as a narcotic drug and that a French ban on hemp derived CBD contradicts EU law. Lees-Buckley says because they...

41 minutes ago

2 min read